“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

Moderna said that the result – which showed its shot was around 26.6% more effective than the comparator – sets up regulatory filings both for mRNA-1010 and its combination flu and COVID-19 ...

A Boston-based nonprofit is among six organizations that on Monday filed a lawsuit against the U.S. Health and Human Services ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Shares of Moderna surged 9.5% on Tuesday to $32.75 in a notable reversal of recent bearish sentiment, buoyed by legal ...

Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine: Cambridge, Massachusetts Wednesday, July 2, 2025, 16:00 Hrs [IST] Moderna, Inc ...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...